• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Role of Lipoprotein(a) in Atherosclerotic Cardiovascular Disease: A Review of Current and Emerging Therapies
AbstractLipoprotein(a), or Lp(a), is structurally like low-density lipoprotein (LDL) but differs in that it contains glycoprotein apolipoprotein(a) [apo(a)]. Due to its prothrombotic and proinflammatory properties, Lp(a) is an independent risk factor for atherosclerotic cardiovascular disease (ASCVD) and aortic valve stenosis. Lp(a) levels are genetically determined, and it is estimated that 20-25% of the global population has an Lp(a) level ≥50 mg/dL (or ≥125 nmol/L). Diet and lifestyle interventions have little to no effect on Lp(a) levels. Lipoprotein apheresis is the only approved treatment for elevated Lp(a) but i...
Source: Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy - July 19, 2023 Category: Drugs & Pharmacology Authors: Ibrahim S. Alhomoud, Azita Talasaz, Anurag Mehta, Michael Kelly, Evan M. Sisson, John D. Bucheit, Roy Brown, Dave L. Dixon Tags: REVIEW Source Type: research

Inclisiran: A First-in-Class siRNA Therapy for Lowering Low-Density Lipoprotein Cholesterol
CONCLUSION: Inclisiran is an effective and safe medication for lowering LDL-C levels. Additional data regarding efficacy on cardiovascular outcomes and long-term safety profile with inclisiran are needed.PMID:35775133 | DOI:10.1177/10600280221105169
Source: The Annals of Pharmacotherapy - July 1, 2022 Category: Drugs & Pharmacology Authors: Essie Samuel Maya Watford Ugochukwu O Egolum David N Ombengi Hua Ling Drew W Cates Source Type: research

Inclisiran: A Novel Small Interfering RNA Drug for LDL Reduction
This article is protected by copyright. All rights reserved.PMID:35279835 | DOI:10.1002/jcph.2045
Source: The Journal of Clinical Pharmacology - March 13, 2022 Category: Drugs & Pharmacology Authors: Kimberly W Smith C Michael White Source Type: research

Inclisiran (Leqvio) for LDL-Cholesterol Lowering
Date: March 21, 2022 Issue #:  1646Summary:  The FDA has approved inclisiran (Leqvio– Novartis), a small interfering RNA (siRNA) directed to proprotein convertase subtilisin/kexin type 9 (PCSK9) mRNA, as an adjunct to diet and maximally tolerated statin therapy for subcutaneous (SC) treatment of adults with heterozygous familial hypercholesterolemia (HeFH) or clinical atheroscler otic cardiovascular disease (ASCVD) who require additional lowering of low-density lipoprotein cholesterol (LDL-C). Inclisiran is the first FDA-approved PCSK9-directed siRNA therapeutic agent.
Source: The Medical Letter - February 8, 2022 Category: Drugs & Pharmacology Authors: admin Tags: alirocumab bempedoic acid evolocumab Ezetimibe Ezetrol Hypercholesterolemia inclisiran Leqvio Nexletol Nexlizet Praluent Repatha Statins Zetia Source Type: research

Inclisiran in lipid management: A Literature overview and future perspectives
Biomed Pharmacother. 2021 Sep 23;143:112227. doi: 10.1016/j.biopha.2021.112227. Online ahead of print.ABSTRACTPrimary and secondary prevention protocols aim at reducing the plasma levels of lipids - with particular reference to low-density lipoprotein cholesterol (LDL-C) plasma concentrations - in order to improve the overall survival and reduce the occurrence of major adverse cardiovascular events. The use of statins has been widely considered as the first-line approach in lipids management as they can dramatically impact on the cardiovascular risk profile of individuals. The introduction of ezetimibe and proprotein conve...
Source: Biomedicine and pharmacotherapy = Biomedecine and pharmacotherapie - September 26, 2021 Category: Drugs & Pharmacology Authors: Pietro Scicchitano Michele Milo Rosanna Mallamaci Micaela De Palo Pasquale Caldarola Francesco Massari Domenico Gabrielli Furio Colivicchi Marco Matteo Ciccone Source Type: research

Inclisiran in dyslipidemia
Drugs Today (Barc). 2021 May;57(5):311-319. doi: 10.1358/dot.2021.57.5.3277083.ABSTRACTCardiovascular disease (CVD) is the leading cause of death worldwide. Hypercholesterolemia has been shown to be one of the most important risk factors for CVD. Statins are currently the standard of care for the management of hypercholesterolemia. However, certain patients on statin therapy fail to achieve the desired low-density lipoprotein cholesterol (LDL-C) goals or are intolerant to statins due to side effects (mostly myalgias). The discovery of proprotein convertase subtilisin/kexin type 9 (PCSK9) and the subsequent development of P...
Source: Drugs of Today - June 1, 2021 Category: Drugs & Pharmacology Authors: C E Kosmas A Mu ñoz Estrella A Sourlas D Pantou Source Type: research

Pages: 1  2  3